T-DM1 gets Priority Review
FDA accepted and granted Priority Review to a BLA from Genentech Inc. for trastuzumab emtansine ( T-DM1) to treat HER2-positive, unresectable locally advanced or metastatic breast cancer in patients who have received...
FDA accepted and granted Priority Review to a BLA from Genentech Inc. for trastuzumab emtansine ( T-DM1) to treat HER2-positive, unresectable locally advanced or metastatic breast cancer in patients who have received...